Michael C. Perry

19.4k total citations · 3 hit papers
198 papers, 14.6k citations indexed

About

Michael C. Perry is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Michael C. Perry has authored 198 papers receiving a total of 14.6k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Oncology, 65 papers in Pulmonary and Respiratory Medicine and 29 papers in Molecular Biology. Recurrent topics in Michael C. Perry's work include Lung Cancer Treatments and Mutations (48 papers), Lung Cancer Research Studies (47 papers) and Cancer Treatment and Pharmacology (25 papers). Michael C. Perry is often cited by papers focused on Lung Cancer Treatments and Mutations (48 papers), Lung Cancer Research Studies (47 papers) and Cancer Treatment and Pharmacology (25 papers). Michael C. Perry collaborates with scholars based in United States, United Kingdom and Switzerland. Michael C. Perry's co-authors include David H. Johnson, Joan H. Schiller, Julie R. Brahmer, Afshin Dowlati, Robert J. Gray, Rogério Lilenbaum, Alan Sandler, Mark R. Green, Paul D. King and Walter L. Eaton and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Michael C. Perry

193 papers receiving 14.0k citations

Hit Papers

Paclitaxel–Carboplatin Al... 1990 2026 2002 2014 2006 1992 1990 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
    2006 4.5k citations Alan Sandler, Robert J. Gray et al. profile →
  2. A Meta-Analysis of Thoracic Radiotherapy for Small-Cell Lung Cancer
    1992 932 citations David H. Johnson, Michael C. Perry et al. profile →
  3. A Randomized Trial of Induction Chemotherapy plus High-Dose Radiation versus Radiation Alone in Stage III Non-Small-Cell Lung Cancer
    1990 882 citations Kathleen J. Propert, Michael C. Perry et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Michael C. Perry 8.4k 7.3k 3.1k 2.0k 1.7k 198 14.6k
John J. Crowley 8.0k 0.9× 8.8k 1.2× 3.9k 1.2× 1.5k 0.8× 1.8k 1.0× 195 17.8k
Karen Kelly 9.4k 1.1× 8.3k 1.1× 3.4k 1.1× 881 0.4× 1.7k 1.0× 390 14.8k
David S. Ettinger 6.2k 0.7× 4.4k 0.6× 2.6k 0.8× 1.8k 0.9× 683 0.4× 280 10.9k
Ramaswamy Govindan 9.1k 1.1× 9.8k 1.3× 5.2k 1.7× 2.1k 1.1× 2.9k 1.7× 482 18.1k
Marianne Paesmans 7.9k 0.9× 4.3k 0.6× 2.3k 0.7× 1.7k 0.8× 2.2k 1.3× 337 13.0k
Mary O’Brien 12.1k 1.4× 8.8k 1.2× 2.3k 0.7× 1.6k 0.8× 2.2k 1.3× 273 17.2k
Nir Peled 10.2k 1.2× 8.9k 1.2× 2.4k 0.8× 1.1k 0.6× 2.0k 1.2× 305 17.9k
Yutaka Nishiwaki 13.4k 1.6× 14.7k 2.0× 4.8k 1.5× 2.3k 1.2× 2.4k 1.4× 272 21.2k
James E. Krook 10.2k 1.2× 5.8k 0.8× 2.5k 0.8× 950 0.5× 1.6k 0.9× 136 14.6k
Betsy Kohler 6.2k 0.7× 2.9k 0.4× 2.6k 0.8× 2.1k 1.1× 2.0k 1.2× 61 13.9k

Countries citing papers authored by Michael C. Perry

Since Specialization
Citations

This map shows the geographic impact of Michael C. Perry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael C. Perry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael C. Perry more than expected).

Fields of papers citing papers by Michael C. Perry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael C. Perry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael C. Perry. The network helps show where Michael C. Perry may publish in the future.

Co-authorship network of co-authors of Michael C. Perry

This figure shows the co-authorship network connecting the top 25 collaborators of Michael C. Perry. A scholar is included among the top collaborators of Michael C. Perry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael C. Perry. Michael C. Perry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wakelee, Heather A., Suzanne E. Dahlberg, Julie R. Brahmer, et al.. (2012). Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. Lung Cancer. 76(3). 410–415. 26 indexed citations
2.
3.
4.
Byrd, John C., Bercedis L. Peterson, R. Kanti, et al.. (2009). Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leukemia & lymphoma. 50(10). 1589–1596. 25 indexed citations
5.
Crawford, Jeffrey, Francisco Robert, Michael C. Perry, Chandra P. Belani, & Denise Williams. (2007). A Randomized Trial Comparing Immediate versus Delayed Treatment of Anemia with Once-Weekly Epoetin Alfa in Patients with Non-small Cell Lung Cancer Scheduled to Receive First-Line Chemotherapy. Journal of Thoracic Oncology. 2(3). 210–220. 23 indexed citations
6.
Weiss, Glen J., Rafael Rosell, Frank V. Fossella, et al.. (2007). The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Annals of Oncology. 18(3). 453–460. 65 indexed citations
7.
Smith, Charles J., et al.. (2006). Evaluation of Combined 177 Lu-DOTA-8-AOC-BBN (7-14)NH 2 GRP Receptor-Targeted Radiotherapy and Chemotherapy in PC-3 Human Prostate Tumor Cell Xenografted SCID Mice. Cancer Biotherapy and Radiopharmaceuticals. 21(2). 155–166. 29 indexed citations
8.
Ramalingam, Suresh S., John Barstis, Michael C. Perry, et al.. (2006). Treatment of Elderly Non–small Cell Lung Cancer Patients with Three Different Schedules of Weekly Paclitaxel in Combination with Carboplatin: Subanalysis of a Randomized Trial. Journal of Thoracic Oncology. 1(3). 240–244. 15 indexed citations
9.
Floyd, Justin D., et al.. (2006). Hepatotoxicity of Chemotherapy. Seminars in Oncology. 33(1). 50–67. 182 indexed citations
10.
Keller, Steven M., Márk Vangel, Henry Wagner, et al.. (2004). Prolonged survival in patients with resected non–small cell lung cancer and single-level N2 disease. Journal of Thoracic and Cardiovascular Surgery. 128(1). 130–137. 72 indexed citations
11.
Foldvary, Nancy, Michael C. Perry, Jungwha Lee, Dudley S. Dinner, & Harold H. Morris. (2001). The Effects of Lamotrigine on Sleep in Patients with Epilepsy. Epilepsia. 42(12). 1569–1573. 69 indexed citations
12.
Kornblith, Alice B., James E. Herndon, Enid Zuckerman, et al.. (2001). Social support as a buffer to the psychological impact of stressful life events in women with breast cancer. Cancer. 91(2). 443–454. 207 indexed citations
13.
Foldvary, Nancy, Anthony C. Caruso, Ed Mascha, et al.. (2000). Identifying Montages that Best Detect Electrographic Seizure Activity During Polysomnography. SLEEP. 23(2). 221–9. 28 indexed citations
14.
Perry, Michael C.. (1999). Companion handbook to The chemotherapy source book. Lippincott Williams & Wilkins eBooks. 11 indexed citations
15.
Luikart, Sharon D., James E. Herndon, Donna Hollis, et al.. (1997). Phase I Trial of Etoposide, Carboplatin, and GM-CSF in Extensive Small-Cell Lung Cancer. American Journal of Clinical Oncology. 20(1). 24–30. 3 indexed citations
16.
Bitran, Jacob D., Mark A. Green, Michael C. Perry, Donna Hollis, & James E. Herndon. (1995). A Phase II Study of Recombinant Interferon-Gamma Following Combination Chemotherapy for Patients with Extensive Small Cell Lung Cancer. American Journal of Clinical Oncology. 18(1). 67–70. 9 indexed citations
17.
Luikart, Sharon D., David A. Van Echo, Caron Modeas, et al.. (1993). Phase I/II Trial of Etoposide and Carboplatin in Extensive Small-Cell Lung Cancer. American Journal of Clinical Oncology. 16(2). 127–131. 13 indexed citations
18.
Komp, Diane M. & Michael C. Perry. (1991). Introduction: The histiocytic syndromes. Seminars in Oncology. 18(1). 1–2. 4 indexed citations
19.
Perry, Michael C. & Robert A. Kyle. (1975). The Clinical Significance of Bence Jones Proteinuria. Mayo Clinic Proceedings. 50(5). 234–238. 27 indexed citations
20.
Blockey, M., et al.. (1973). Steroid plasma levels about oestrus in the beef cow. Reproduction. 32(2). 342–343. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John J. Crowley Breakdown of academic impact, for papers by Karen Kelly Breakdown of academic impact, for papers by David S. Ettinger Breakdown of academic impact, for papers by Ramaswamy Govindan Breakdown of academic impact, for papers by Marianne Paesmans Breakdown of academic impact, for papers by Mary O’Brien Breakdown of academic impact, for papers by Nir Peled Breakdown of academic impact, for papers by Yutaka Nishiwaki Breakdown of academic impact, for papers by James E. Krook Breakdown of academic impact, for papers by Betsy Kohler
Rankless by CCL
2026